Inventor · disambiguated record
Harsh Shah
Also filed as: SHAH HARSH · SHAH HARSH S · SHAH HARSH SHAILESH
5 granted patents·3 pending applications·18 citations·filing 2012–2025
73Inventor score
Files withEVONIK OPERATIONS GMBH2IO THERAPEUTICS INC2BLUEPRINT MEDICINES CORP1BOEHRINGER INGELHEIM INT1JOSHI SHRADDHA SANJEEV1
Top patents by PatentIndex Score
8 records- 0193US11919848B2RXR agonist salt form, polymorphs thereof, and uses thereofIO THERAPEUTICS INC·Filed 2023·Granted Mar 5, 2024·1 cites·20 claims
- 0285US12325685B2RXR agonist salt form, polymorphs thereof, and uses thereofIO THERAPEUTICS INC·Filed 2024·Granted Jun 10, 2025·0 cites·9 claims
- 0385US10639283B2Gastric resistant pharmaceutical or nutraceutical composition with resistance against the influence of ethanolEVONIK OPERATIONS GMBH·Filed 2012·Granted May 5, 2020·7 cites·17 claims
- 0483US9895318B2Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanolJOSHI SHRADDHA SANJEEV·Filed 2015·Granted Feb 20, 2018·9 cites·21 claims
- 0571US10842752B2Pharmaceutical or nutraceutical composition with sustained release characteristic and with resistance against the influence of ethanolEVONIK OPERATIONS GMBH·Filed 2012·Granted Nov 24, 2020·1 cites·15 claims
- 0663US2024270719A1Crystalline forms of 2-(4-(4-(aminomethyl)-1-oxo-1,2-dihydrophthalazin-6-yl)-1-methyl-1h-pyrazol-5-yl)-4-chloro-6-cyclopropoxy-3-fluorobenzonitrileMIRATI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 0759US2025282761A1Salt and crystal forms of an epidermal growth factor receptor inhibitorBLUEPRINT MEDICINES CORP·Filed 2023·Application pending·0 cites
- 0850US2025376476A1Crystalline forms of a HER2 tyrosine kinase inhibitorBOEHRINGER INGELHEIM INT·Filed 2025·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Harsh Shah files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →